Novartis Income Tax Expense Over Time
| NVS Stock | USD 112.13 1.08 0.95% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Novartis Performance and Novartis Correlation. Novartis |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.66) | Dividend Share 3.862 | Earnings Share 5.88 | Revenue Per Share | Quarterly Revenue Growth 0.151 |
The market value of Novartis AG ADR is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Income Tax Expense Analysis
Compare Novartis AG ADR and related stocks such as AstraZeneca PLC ADR, GlaxoSmithKline PLC ADR, and Roche Holding Income Tax Expense Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZN | 231.5 M | 2.4 B | 1.4 B | 696 M | 11 M | 243 M | 146 M | (641 M) | (57 M) | 321 M | 772 M | (380 M) | (792 M) | 938 M | 1.6 B | 1.7 B |
| GSK | 209 M | 2.2 B | 1.9 B | 1 B | 137 M | 2.2 B | 877 M | 1.4 B | 754 M | 953 M | 580 M | 346 M | 707 M | 756 M | 526 M | 499.7 M |
| BMY | 560 M | 1.7 B | (161 M) | 311 M | 352 M | 477 M | 1.4 B | 4.2 B | 1 B | 1.5 B | 2.1 B | 1.1 B | 1.4 B | 400 M | 554 M | 526.3 M |
| SNY | 292 M | 440 M | 1.1 B | 726 M | 1.2 B | 709 M | 1.3 B | 1.7 B | 481 M | 121 M | 1.8 B | 1.6 B | 2 B | 1.6 B | 1.2 B | 1.1 B |
| MRK | 317.1 M | 942 M | 2.4 B | 1 B | 5.3 B | 942 M | 1.8 B | 4.2 B | 2.5 B | 1.7 B | 1.7 B | 1.5 B | 1.9 B | 1.5 B | 2.8 B | 2 B |
| GILD | (1.6 M) | 861.9 M | 1 B | 1.2 B | 2.8 B | 3.6 B | 3.6 B | 8.9 B | 2.3 B | (204 M) | 1.6 B | 2.1 B | 1.2 B | (1.2 B) | 211 M | 200.4 M |
| JNJ | 285.5 M | 2.7 B | 3.3 B | 1.6 B | 4.2 B | 3.8 B | 3.3 B | 16.4 B | 2.7 B | 2.2 B | 1.8 B | 1.4 B | 3 B | 1.7 B | 2.6 B | 2.6 B |
| ABBV | 1.3 B | 235.4 M | 450 M | 1.2 B | 595 M | 1.5 B | 1.9 B | 2.4 B | (490 M) | 544 M | 1.2 B | 1.4 B | 1.6 B | 1.4 B | (570 M) | (541.5 M) |
| LLY | 279 M | 1 B | 1.3 B | 1.2 B | 609.8 M | 381.6 M | 636.4 M | 2.4 B | 529.5 M | 628 M | 1 B | 573.8 M | 561.6 M | 1.3 B | 2.1 B | 2.2 B |
| PFE | 296.4 M | 4 B | 2.6 B | 4.3 B | 3.1 B | 2 B | 1.1 B | (9 B) | 706 M | 1.4 B | 477 M | 1.9 B | 3.3 B | (1.1 B) | (28 M) | (26.6 M) |
Novartis AG ADR and related stocks such as AstraZeneca PLC ADR, GlaxoSmithKline PLC ADR, and Roche Holding Income Tax Expense description
My Equities
My Current Equities and Potential Positions
| Novartis AG ADR | NVS |
| Classification | Healthcare |
| Location | Switzerland |
| Exchange | New York Stock Exchange |
USD 112.13
Additional Tools for Novartis Stock Analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.